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Abstract
Cystic Fibrosis (CF), caused by mutations affecting the CFTR gene, is characterised by
viscid secretions in multiple organ systems. CF airways contain thick mucus, creating a
gradient of hypoxia, which promotes the establishment of polymicrobial infection. Such
inflammation predisposes to further infection, a self-perpetuating cycle in mediated by NF-
κB. Anaerobic Gram-negative Prevotella spp. are found in sputum from healthy volunteers
and CF patients and in CF lungs correlate with reduced levels of inflammation. Prevotella
histicola (P. histicola) can suppress murine lung inflammation, however, no studies have
examined the role of P. histicola in modulating infection and inflammation in the CF air-
ways. We investigated innate immune signalling and NF-kB activation in CF epithelial cells
CFBE41o- in response to clinical stains of P. histicola and Pseudomonas aeruginosa
(P. aeruginosa). Toll-Like Receptor (TLR) expressing HEK-293 cells and siRNA assays
for TLRs and IKKα were used to confirm signalling pathways. We show that P. histicola
infection activated the alternative NF-kB signalling pathway in CF bronchial epithelial cells
inducing HIF-1α protein. TLR5 signalling was responsible for the induction of the alterna-
tive NF-kB pathway through phosphorylation of IKKα. The induction of transcription factor
HIF-1α was inversely associated with the induction of the alternative NF-kB pathway and
knockdown of IKKα partially restored canonical NF-kB activation in response to P. histi-
cola. This study demonstrates that different bacterial species in the respiratory micro-
biome can contribute differently to inflammation, either by activating inflammatory
cascades (P. aeruginosa) or by muting the inflammatory response by modulating similar
or related pathways (P. histicola). Further work is required to assess the complex interac-
tions of the lung microbiome in response to mixed bacterial infections and their effects in
people with CF.
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Introduction
Cystic Fibrosis (CF), is an autosomal recessive life-limiting disease, characterised by viscid
secretions in multiple organ systems due to mutations affecting the CFTR gene, which codes
for a cAMP-regulated chloride channel, found on epithelial surfaces, including the airways,
pancreas, and intestine [1]. To date over 2000 mutations have been described, with a phenyl-
alanine deletion (F508del) being the most common disease-causing mutation (present in
~90% of PWCF). The main causes of mortality and morbidity in CF are lung damage and pro-
gressive lung function decline and, attributed in part to the dehydrated mucus and bacterial
infection with Gram-negative pathogens which cause a sustained inflammatory response in
the CF lung [2]. The contribution of bacterial species such as Pseudomonas aeruginosa (P. aer-
uginosa), Burkholderia cepacia complex, Haemophilus influenza and Staphylococcus aureus
(S. aureus) to inflammation in the CF lung have been extensively studied [3–5], however, a
broader picture of the microenvironment in the CF lung has recently become apparent with
advances in high fidelity next generation sequencing (NGS) [1]. This method has identified
a diverse microbiome in the lungs of people with CF, including the presence of the Gram-
negative anaerobic genus Prevotella spp. [6]. Members of this genus are also found in high
abundance in the upper airway of healthy people [7], but its role in the airways is poorly char-
acterised. In people with CF the presence of Prevotella spp. has a positive correlation with
higher lung function and reduced C-reactive protein (CRP) [8]. Furthermore, we recently
showed that a strain of P. nigrescens isolated from a person with CF induced a lower pro-
inflammatory cytokine expression in CF bronchial epithelial cells than P. aeruginosa, suggest-
ing that the presence of certain Prevotella species in CF lungs may lower the inflammatory
response and could therefore be beneficial to the host [9].
Interaction of bacterial pathogen the host cells (the airway epithelia cells) results in the acti-
vation of Toll-Like Receptors (TLRs) such as TLR2 (recognising mainly Gram-positive bacte-
ria) and TLR4 (recognising mainly Gram-negative bacteria). In airway epithelial cells, such
TLR-ligand binding activates NF-κB signalling leading to the induction of the innate inflam-
matory response.
NF-κB activation occurs via two major signalling pathways, the canonical and the non-
canonical NF-κB signalling pathways. Common to both is the activation of the IκB kinase
(IKK) complex (IKKα/IKKβ) [10]. In the canonical signaling pathway, binding of ligands to
cell surface receptors such as Toll-like receptors (TLRs) lead to the recruitment of adaptors
such as TRAF to phosphorylate IKK. Subsequent phosphorylation and degradation of IκB acti-
vates and translocates NF-κB dimers comprising RelA(p65), c-Rel, RelB and p50 to induce tar-
get gene expression [11]. Activation of the non-canonical pathway, involves the two IKKα
subunits containing IKK complex, but not NEMO. Ligand-induced activation triggers NF-κB
inducing kinase (NIK) to phosphorylate and activate the IKKα complex. In turn, IKKα phos-
phorylates p100 leading to the p52/RelB active heterodimer, important e.g. for the generation
of B and T lymphocytes. Importantly, to date, only a small number of stimuli are known to
activate the non-canonical pathway [12].
In CF airway diseases, the canonical NF-κB signalling pathway, consisting of the p65 and
p50 subunits, and its role in inflammation in CF has been extensively investigated [9, 13, 14],
however, the role of the alternative NF-κB signalling pathway, involving RelB and p52 sub-
units, has not. Activation of the alternative pathway is known to occur in response to a small
set of agonists including lipopolysaccharide (LPS), CD40Ligand and lymphotoxin-alpha (LT-
α1). This pathway has been shown to be active in epithelial cells and has recently been impli-
cated in pathway analysis of inflammation in people with CF [15–17]. Inhibitor of kappaB
kinase α (IKKα) plays a role in resolving NF-κB-driven inflammation in TLR expressing cells
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by facilitating turnover of p65 and cRel, removing them from the nucleus [18]. Thereby IKKα
activation was also shown to limit the inflammatory response during bacterial infection and
inhibit canonical NF-κB activation [18].
Furthermore, mucus plugging and bacterial bio-film development results in the formation
of gradients of hypoxia in the CF lung supporting induction of the transcription factor hypoxia
induced factor-1α (HIF-1α). The relationship between induction of HIF-1α and NF-κB signal-
ling indicates that the induction of HIF-1α may exert a regulatory effect on p65-driven inflam-
mation [19]. However, the effect of HIF-1α on the alternative NF-κB pathway and possibly the
resolution of inflammation is not clearly understood [20].
No studies have examined if infection with P. histicola results in the activation of TLR sig-
nalling pathways in CF bronchial epithelial cells and if TLR signalling can directly activate the
alternative NF-κB signalling pathway in CF bronchial epithelial cells. As bacterial infection
results in NF-κB signalling and induction of inflammatory cytokines, we hypothesised that P.
histicola induces TLR signalling contributing to the activation of NF-κB signalling. As the
presence of Prevotella spp. in CF lungs correlates with better lung function [8], we further
hypothesised P. histicola may activate the alternative NF-κB driven response, which may
inhibit canonical NF-κB activation [21]. These studies demonstrate that P. histicola activates




The bacterial isolates used in this study were all obtained from patients attending the adult CF
clinic at Belfast City Hospital. The isolates were derived from two different patients enrolled in
a multicentre study (Office for Research Ethics Committees Northern Ireland (OREC) 10/
NIR01/41; Integrated Research Approval System (IRAS) Project no. 41579) as previously
described [17].
The clinical isolate of P. histicola B011L was cultured under anaerobic conditions for 72
hours on Columbia Blood Agar (CBA, Fannin LIP) using a Don Whitley anaerobic cabinet
(Don Whitley A35 workstation) as described [6]. This lawn of colonies was used to inoculate
10mL of anaerobic basal broth (Oxoid)TO OD.0.1 and this was allowed to grow to mid log
phase (approximately 18 hours). This culture was used for infection experiments. P. histicola
was identified by 16S rRNA sequencing, PGFE and RAPD analysis as described [9, 22].
P. aeruginosa (clinical isolate B021, identified using 16S rRNA screening [22]) was grown
under aerobic conditions on Columbia blood agar (CBA) (37˚C, 5% CO2, 95% mixed gas)
over night. This culture was then utilised to inoculate a 10 mL culture of Lysogeny Broth (LB
broth), The start OD was 0.05. This broth culture was incubated for up to two hours at 200
rpm, 37˚C until mid-log phase under aerobic conditions (approximately 3–4 hours) prior to
being used for further cell infections under anaerobic conditions.
The minimum amount of bacteria required to provoke a significant response from
CFBE41o- cells (0-4h, anaerobic conditions) was determined by screening of 3 different P. aer-
uginosa isolates as described [9]. Growth curves of P. histicola and P. aeruginosa under anaero-
bic conditions revealed no differences in the growth rates between the two species (S1 Fig).
Cell culture
The F508del homozygote cystic fibrosis cell line (CFBE41o-) was maintained in antibiotic free
minimum essential media (MEM, Gibco), supplemented with 10% heat inactivated foetal
bovine serum (FBS, Gibco) and 5% L-Glutamine (Gibco) under standard cell culture
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conditions (37˚C, 5% CO2, 95% mixed gas). All tissue culture flasks and plates were pre-coated
with a 1% PurCol type 1 collagen solution (Nutacon) and passaged as described previously
[23]. HEK-293-TLR2, HEK-293-TLR4, HE-293-TLR5 and HEK-293-TLR null cells were
maintained as per manufacturer’s instructions (InvivoGen).
Infection assays
CFBE41o- cells were infected with P. histicola or P. aeruginosa at an MOI (Multiplicity of
Infection) of 100 for 4 hours. Both bacteria were grown to mid log phase as described previ-
ously [9]. An MOI of 100 was defined by plating all inocula on CBA agar and enumerating via-
ble counts the following morning. Liquid cultures were used to inoculate cells for infection
experiments and cells were incubated for up to 4 hours under anaerobic conditions as
described above. Cells were incubated under anaerobic conditions for the duration of the
experiments as described in supplementary data (S1 Text).
Cell viability assays
To confirm that experimental conditions would not negatively affect cell viability, lactate dehy-
drogenase release (LDH, Abcam), mitochondrial respiration (MTT) and trypan blue exclusion
were assessed after exposure to hypoxia and bacteria.
Briefly, bell death was assessed by measuring LDH release from infected cells and non-infected
control cells. 10μL of supernatant was used for each assay as per manufacturer’s instructions
(Abcam, ab69693). Analyses of mitochondrial activation (measured by MTT (3- [4, 5-dimethyl
thiazol-2yl]– 2, 5 diphenyl tetrazolium bromide) conversion to purple formazan (absorbance λ =
570nm)) served as a surrogate for cell viability. Trypan Blue (Sigma) was used in the dye exclusion
assay. After incubation and loading onto a Neubauer haemocytometer, cells which appeared blue
under the microscope were determined as ‘dead’ and cells appearing white were counted as ‘live
cells’. Further details of these assays can be found in the supplement (S2A–S2C Fig).
TLR reporter assays
HEK-293-TLR2, HEK-293-TLR4 and HEK-293-TLR5 cells were purchased from InvivoGen
and cultured and transfected as per manufacturer’s instructions. Briefly, HEK-293 cells were
maintained in high Glucose DMEM with 10% FBS, L-Glutamine and Pen/Strep. 100μg Blasti-
cidin was added to cells after the second passage and cells were maintained in the media there-
after. Cells were transiently transfected with an NF-κB containing reporter construct plasmid
(LyoVec and pNifty-Luc™, InvivoGen) and cells were incubated for 24 hours under standard
tissue culture conditions to recover from the transfection. Bacterial infection was carried out
as described [9] and cells were incubated under anaerobic conditions for the duration of the
experiments.
Cytoplasmic and nuclear fraction extraction for DNA binding ELISA
CFBE41o- cells were infected with either P. aeruginosa or P. histicola as described. DNA-bind-
ing ELISAs (enzyme-linked immunosorbent assays) were commercially sourced. (i) IKKα:
Solid phase ELISA (Cell signal, CST, PathScan Phospho-IKKα). IKKα was quantified from all
samples at 0–240 minutes as per manufacturer’s instructions. (ii) IκBα (Inhibitor of kappa-B
alpha): Sandwich ELISA to quantify phosphorylated IκBα in infected and non-infected cells at
0–120 minutes after infection (Function ELISA IκBα, S32/S36, Active Motif). (iii) NF-κB:
DNA-binding ELISA to quantify active p65, p50, RelB and p52 subunits in infected and non-
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infected cells (Trans/AM NFκB, Activ Motif). Nuclear cell fractions were generated using the
NE-PerTM nuclear and cytoplasmic extraction reagents (Thermo Fisher Scientific).
RT-PCR for TLR and cytokine gene expression
Total RNA was extracted from infected and un-infected control cell populations using a com-
bination of TRIzol™ extraction reagent and column extraction as per manufacturer’s instruc-
tions (Ambion/Thermo Fisher Scientific). Deoxyribonuclease (DNAse) digestion was carried
out as per manufacturer’s instructions using DNAse 1 (Thermo Fisher Scientific) for each
sample. Reverse transcription was carried out using 0.5μg total RNA for each reaction (Super-
script III reverse transcription kit, Thermo Fisher Scientific).
Quantitative reverse transcription PCR (qRT-PCR) analysis was carried out on an
MX300-P (Agilent technologies) using gene specific primers (QuantiTect1, Qiagen) and SyBr
Green PCR master mix (Thermo Fisher Scientific) as per manufacturer’s instructions. The
endogenously expressed beta-2-microglobulin (B2M) was used as a house-keeping gene in all
experiments. Relative gene expression was calculated as 2^-ΔΔCT.
siRNA knockdown assays
Silencer RNA (siRNA) targeted against TLR2, TLR5, scrambled siRNA and siRNA targeted
against IKKα (Silencer select, Thermo Fisher Scientific). Lipofectamine 2000 was utilised and
reverse transfection was used in all siRNA assays (Thermo Fisher Scientific). Target gene and
protein expression were assessed at 24–48 hours post transfection. Lipofectamine did not
induce any significant increase in LDH release (S3 Fig). SiRNA and Lipofectamine concentra-
tions were optimised to induce a significant reduction in target gene expression (S4A Fig) and
subsequent cytokine release (S4B Fig).
Statistical analysis
All statistical analyses were performed using GraphPad Prism (v5.0; GraphPad, San Diego,
CA). All data are expressed as mean +/- standard deviation (SD). Parametric tests including
Student’s t-test were employed to assess the null hypothesis. Where more than two groups
were compared either one- or two-way ANOVA was utilised to assess differences between the
mean or differences between matched samples with a post-hoc Bonferroni analysis performed
for all tests utilising one-way ANOVA.
Further information to materials & methods can be found in the supplement (S1 Text).
Results
Inflammatory pathway analyses for P. histicola
To test the hypothesis that infection with P. histicola in CF airway epithelial cells may contrib-
ute to anti-inflammatory signalling through activation of the alternative NF-κB pathway we
compared NF-κB signalling in CFBE41o- cells infected with P. histicola and P. aeruginosa.
Only P. aeruginosa infection increased phosphorylated IκBα (at 10 min vs 0 min) compared
to non-infected control cells (p<0.01), which returned to baseline at 30 min post infection
(Fig 1A). Infection with P. aeruginosa also induced significantly higher levels of nuclear
p65-DNA binding (2 and 4 hours, p<0.001 and p<0.01, Fig 1B) and significantly higher
nuclear p50-DNA binding in response to infection (at 4 hours, p<0.001, Fig 1C), but P. aerugi-
nosa did not change nuclear RelB- or p52-DNA binding (Fig 1D and 1E). In contrast,
CFBE41o- cells infected with P. histicola did not demonstrate elevated levels of phosphorylated
IκBα at any time point and there was no change in nuclear p50 or p65 in response to infection
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Fig 1. P. histicola–Inflammatory pathway analyses. CFBE41o- cells were infected with P. aeruginosa or P. histicola (MOI 100 for up to 4 hours,
anaerobic conditions). A: Quantification of phosphorylated IκBα (pg/mL) in CFBE41o- cells infected with P. aeruginosa or P. histicola 0–60 minutes
post infection. The DNA-binding abilities of p65, RelB and p52 were determined 2- and 4-hours post infection. B: DNA binding of p65 in infected and
non-infected CFBE41o- cells. C: DNA binding of p50 in response to infection in CFBE41o- cells. D: RelB-DNA-binding in response to infection in
CFBE41o- cells. E: DNA-binding of p52 in infected CFBE41o- cells. Quantitative RT-PCR using SyBr Green was carried out to determine mRNA
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(Fig 1A–1C). However, significant levels of nuclear RelB were observed in response to infec-
tion with P. histicola (2 hours, p<0.001) with a reduction at 4 hours post infection compared
to baseline controls (Fig 1D). Additionally, nuclear p52-DNA binding was increased 2 hours
post infection with P. histicola with a significant reduction observed by 4 hours post infection
(p<0.05, Fig 1E).
As we did not observe nuclear p65-DNA binding in response to infection with P. histicola,
we hypothesised that infection with P. histicola would not result in transcription of NF-κB
driven inflammatory cytokines. While P. aeruginosa infection resulted in significant induction
of gene expression for interleukin (IL-)6, IL-8 and CXCL-1 in CFBE41o- cells (4 hours, Fig
1F–1H), there was no IL-8 or CXCL-1 gene induction in response to infection with P. histicola
at any time point (Fig 1G and 1H). A significant increase in IL-6 gene expression was observed
in CFBE41o- cells at 2 hours in response to infection with P. histicola (p<0.001, Fig 1F).
Taken together, these data indicate that P. histicola infection in CFBE41o- cells results in
activation of the alternative NF-κB signalling pathway with no activation of the classic NF-κB
pathway.
P. histicola infection and TLR activation
P. aeruginosa signalling via TLR4 and TLR5 is well-established [24, 25], but little is known
about Prevotella-induced TLR signalling. Therefore, to establish events upstream of NF-κB sig-
nalling utilised by P. histicola, we first investigated TLR receptor activation.
HEK-293-TLR4 cells demonstrated TLR4 signalling in response to infection with P. aerugi-
nosa only (1–4 hours post infection, p<0.001), but no TLR4 signalling was observed after
infection with P. histicola (Fig 2A). HEK-293-TLR2 cells showed TLR2 signalling 2 and 4
hours after P. histicola infection (both p<0.001, Fig 2B). P. aeruginosa infection lead to TLR2
signalling 4 hours after infection only (p<0.01, Fig 2B).
Furthermore, using HEK-293-TLR5 cells we observed TLR5 signalling 2 and 4 hours post
infection with P. aeruginosa (p<0.01 and p<0.001) and also after P. histicola infection (p<0.001
and p0.01) with a significant reduction at 4 hours compared to 2 hours (p<0.01, Fig 2C).
To confirm that TLR2 and TLR5 signalling following P. histicola infection would lead to
NF-κB activation, CFBE41o- cells were transiently transfected with siRNA targeted against
TLR2 or TLR5 and infected with P. histicola. In response to infection we observed reduced lev-
els of RelB DNA-binding in cells transfected with siRNA targeted against TLR5 (p<0.001, Fig
2D), but not when cells were transfected with siRNA targeted against TLR2 (Fig 3D). We also
did not find any significant reduction in RelB DNA-binding in response to flagellin stimula-
tion in these cells. However, flagellin alone significantly induces p65-DNA binding in CFBE41
cells (p<0.001, Fig 2E), but has no effect on RelB-DNA binding (Fig 2D). As a control, P. aeru-
ginosa infection in TLR2 and TLR5 transfected cells did not lead to any significant changes in
nuclear p65-DNA binding (Fig 2E).
Overall, these results show that P. histicola engages with CF epithelial cells via TLR5 and
does not engage TLR2 signalling.
IKKα in P. histicola infection
A role for IKKα in the regulation of canonical NF-κB-driven inflammation in macrophages
has been described previously [18], but a role in the alternative NF-κB signalling is not known.
expression Beta-2-microglobulin was used as the endogenously expressed house-keeping gene for all experiments and 2-ΔΔCT was calculated for F: IL-6
mRNA, G: IL-8 mRNA and H: CXCL-1. 2-Way ANOVA with Bonferroni post-test, n = 3–5, �p<0.05, ��p<0.01 and ���p<0.001 compared to non-
infected CFBE41o-.
https://doi.org/10.1371/journal.pone.0235803.g001
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Fig 2. P. histicola–TLR pathway signalling analyses. Luminescence release from HEK-293-TLR2, HEK-293-TLR4, HEK-293-TLR5 or HEK-
293-TLRnull cells was determined at up to 4 hours post infection normalised to the results observed from HEK-293-TLRnull cells. A: TLR4
signalling, B: TLR2 signalling; C: TLR5 signalling. 2-Way ANOVA with Bonferroni post-test, n = 3–5, ��p<0.01 and ���p<0.001 compared to non-
infected CFBE41o-. CFBE41o- cells (infected with P. aeruginosa, flagellin or P. histicola under anaerobic conditions (MOI 100 for up to 4 hours)
were transiently transfected with siRNA targeted against TLR2, TLR5, a scrambled transfection or a sham transfection. Nuclear protein was
extracted 2 hours post infection and RelB-DNA binding was determined in transfected and non-transfected cells. D: Nuclear RelB-DNA binding in
TLR2 and TLR5 siRNA transfected CFBE41o- cells. E: Nuclear p65-DNA binding in TLR2 and TLR5 siRNA transfected CFBE41o- cells. 1-Way
ANOVA with Bonferroni post-test, n = 3–9, ���p<0.001 compared to non-infected CFBE41o-; $ $ $p<0.001 compared to P. histicola.
https://doi.org/10.1371/journal.pone.0235803.g002
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To investigate the role of IKKα in NF-κB signalling, we determined phosphorylated IKKα in
P. histicola infection and in CFBE41o- cells with transient IKKα knock down. CFBE41o- cells
rapidly elevated phosphorylated IKKα in response to infection with P. histicola (5–60 min,
p<0.05, p<0.001, Fig 3A), while infection with P. aeruginosa resulted in phosphorylation of
IKKα at 60 minutes post infection only (p<0.001, Fig 3A). siRNA knockdown of IKKα
resulted in a significant reduction in the DNA-binding abilities of nuclear RelB in response to
infection with P. histicola (p<0.001, Fig 3B). As expected, P. aeruginosa infection significantly
induced p65-DNA binding (p<0.001, Fig 3C), but P. histicola infection did not (scrambled
IKKα siRNA and P. histicola, Fig 3C). siRNA IKKα in P. histicola infected CFBE41o- had no
inducing effect on p65-DNA binding in CFBE41o-, and p65-DNA levels remained signifi-
cantly lower compared to those in P. aeruginosa infected cells (p<0.001, Fig 3C). Our results
confirm a role for P. histicola-induced IKKα in alternative NF-κB signalling.
HIF-1α in P. histicola infection
HIF-1α, induced in response to anaerobic conditions, is thought to have a regulatory effect on
NF-κB [26]. Therefore, we assessed if HIF-1α influenced NF-κB activation in response to
infection with P. histicola. CFBE41o- cells had increased levels of HIF-1α protein in response
to infection with P. histicola (1 and 4 hours, both p<0.01, Fig 4A). When CFBE41o- cells were
transfected with siRNA targeting TLR2, intracellular HIF-1α levels remained elevated. How-
ever, in cells transfected with siRNA targeting TLR5, HiF-1α was significantly reduced in
response to infection with P. histicola (30 min, p<0.001, Fig 4B) suggesting that P. histicola
induced TLR5 signalling was mediated by HIF-1α.
Discussion
In CF airways, infections with bacterial species such as P. aeruginosa, Burkholderia cepacia
complex, Haemophilus influenza and S. aureus are well investigated [3–5]. However, advances
in NGS have identified the presence of Prevotella spp. in the lungs of people with CF [6]. More-
over, no studies have examined the ability of TLR signalling to activate the alternative NF-κB
signalling pathway or the role of transcription factor HIF-1α in this CF bronchial epithelial
cells response [27]. Therefore, this study was set out to investigate the contribution of Prevo-
tella spp. (P. histicola) in TLR and NF-κB signalling to CF airways inflammation.
The relative abundance of anaerobic bacteria compared to aerobic bacteria in CF sputum is
associated with a milder disease when compared to Pseudomonas-dominated patients. In this
large multisite study involving clinical stable CF patients from the UK, Ireland and the US,
Muhlebach et al. showed the culture of 18 anaerobic genera from 59% of sputum samples
(95% aerobic). Significantly prevalent anaerobes were Prevotella species, followed by Veillo-
nella, Porphyromonas and others. Importantly, the prevalence of anaerobes was positively asso-
ciated with pancreatic sufficiency, better nutrition and better lung function [28]. Consistent
with this, reduced bacterial diversity and increased levels of inflammation have also been
reported in patients with CF [8, 29]. A lower abundance of aerobic and anaerobic bacteria
reflecting microbiota disruption was also shown to be associated with disease progression
(lower lung clearance index (LCI) and higher CRP in the CF lung [29]. Zemanick et al. investi-
gated the presence of anaerobes in early CF exacerbations showing the highest relative abun-
dance for Prevotella, Veillonella and Porphyromonas. Higher levels of sputum anaerobes were
associated with less inflammation and higher lung function compared to the presence of Pseu-
domonas at exacerbation [8]. However, hile the weak inflammatory properties of commensal
Prevotella spp. might help the airways’ immune system tolerate colonisation [30], P. histicola
has also been shown to exert anti-inflammatory properties in a murine model of rheumatoid
PLOS ONE P. histicola in Cystic Fibrosis activates alternative NF-κB signalling
PLOS ONE | https://doi.org/10.1371/journal.pone.0235803 October 8, 2020 9 / 19
PLOS ONE P. histicola in Cystic Fibrosis activates alternative NF-κB signalling
PLOS ONE | https://doi.org/10.1371/journal.pone.0235803 October 8, 2020 10 / 19
arthritis [31]. Our data confirm that P. histicola contributes to anti-inflammatory signalling,
facilitated through activation of the alternative NF-κB pathway via RelB and p52, while P. aeru-
ginosa signalling is through IκBα phosphorylation and p65/p50 activation.
Hypoxia can affect bacterial growth and Schaible et al. showed that P. aeruginosa growth
was slower under hypoxic conditions than under normoxic conditions [32]. However, com-
paring P. histicola and P. aeruginosa under anaerobic conditions revealed no differences in
growth rates between the two species (S1 Fig), suggesting that any differences described are a
direct result of a different pathway activation.
Our subsequent investigation of TLR receptor activation demonstrated a role for P. histicola
in TLR5-induced activation of the alternative NF-κB signalling in CF bronchial epithelial cells.
Additionally, we demonstrate a role for IKKα and the induction of HIF-1α in regulating CF
inflammation. TLR signalling and the resulting inflammation has been extensively studied in
CF. TLRs (especially TLR2, 4 and 5) in the CF lung are one of the most common innate
immune defences activated in response to infection leading to the activation of the classical
NF-kB-activation and subsequent pro-inflammatory cytokine release [33–36].
Using TLR transfected HEK-293 reporter cells, we have shown that P. histicola infection
induced TLR2 signalling (at 4 hours) and importantly a rapid induction in TLR5 signalling,
which was significantly reduced by the end of the 4 hour infection period. Having established
the TLR signalling route of P. histicola in CF bronchial epithelial cells, we further investigated
the downstream signalling. Infection with P. histicola resulted in the induction of RelB and
p52 protein but not p65 or p50 protein, clearly indicating the induction of the alternative NF-
κB pathway. Alternative NF-κB signalling is involved in cell survival and proliferation and has
been shown to have anti-inflammatory effects. Studies in RelB deficient mice demonstrated an
anti-inflammatory role for RelB [37, 38]. In human lung fibroblasts, RelB overexpression
reduced IL-1β-induced inflammation [39]. Furthermore, RelB has been linked to the develop-
ment of tolerance in THP-1 cells [40] through repression of TNFα and Il-1β [41]. Mechanisti-
cally, RelB may regulate IkBα stability and may thereby limit the canonical NF-kB activation
[42]. Others have suggested that RelB may interfere with NF-kB activity in the nucleus through
protein–protein interactions with RelA to form inactive complexes leading to down-regulation
of NF-κB target genes [43–45]. Alternative NF-κB signalling through anti-inflammatory RelB
may therefore explain why in patients with CF Prevotella spp. in sputum have been associated
with improved lung function and reduced inflammation in CF [8]. This is further supported
by our findings that gene expression of the canonical NF-κB-dependent cytokines IL-8 and
CXCL-1 were not observed at any time point in response to infection with P. histicola.
Increased IL-6 gene expression was observed at 2 hours post infection with P. histicola with a
reduction at 4 hours, indicating a possible role for the alternative NF-κB signalling pathway in
the regulation of IL-6 gene expression, or/and a role for IKKα in the regulation of IL-6 gene
expression [46].
Our data demonstrate signalling through TLR5 by the clinical P. histicola strain used. The
siRNA experiments not only confirmed the activation of TLR5 signalling in CF bronchial
Fig 3. IKKα in P. histicola infection. Phosphorylated IKKα in infected and non-infected CFBE41o- cells (MOI 100, P.
aeruginosa and P. histicola) determined at 0–60 minutes. CFBE41o- cells were also transiently transfected with siRNA
targeted against IKKα. RelB and p65-DNA binding was determined in P. histicola infected cells (MOI 100, for 2
hours). A: Time course IKKα phosphorylation in CFBE41o- cells in response to infection. 2-Way ANOVA with
Bonferroni post-test, n = 3–5, �p<0.05 and ���p<0.001 compared to non-infected CFBE41o-. B: Nuclear RelB-DNA
binding in response to transfection with IKKα siRNA and infection with P. histicola. C: Nuclear p65-DNA binding in
response to transfection with IKKα siRNA and infection with P. histicola. 1-Way ANOVA with Bonferroni post-test,
n = 3–9, ���p<0.001 compared to non-infected CFBE41o-; $ $ $p<0.001 compared to P. histicola (RelB) or P.
aeruginosa (p65).
https://doi.org/10.1371/journal.pone.0235803.g003
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epithelial cells in response to P. histicola, but also that the induction of RelB in P. histicola
infection was a downstream result of TLR5 signalling. Using flagellin alone to activate TLR5,
we clearly show that such activation leads to NF-κB(p65) activation and does not include acti-
vation of RelB. So far, flagellin is the main ligand identified for TLR5 [47]. In P. aeruginosa
Fig 4. HIF-1α in P. histicola infection. A: Time course HIF-1α protein induction in CFBE41o- cells in response to
infection. CFBE41o- cells were transfected with P. aeruginosa or P. histicola (MOI 100) and incubated under anaerobic
conditions for up to 4 hours. Total HIF-1α protein was determined at 1, 2 and 4 hours post infection. 2-Way ANOVA
with Bonferroni post-test, n = 3, ��p<0.01 compared to non-infected CFBE41o-. B: CFBE41o- cells were transiently
transfected with siRNA targeted against TLR2 and TLR5, infected with P. histicola (MOI 100) and incubated under
anaerobic conditions for 30 minutes. Total HIF-1α protein was determined in transfected and non-transfected cells in
response to infection. 1-Way ANOVA with Bonferroni post-test, n = 4, ���p<0.001 compared to non-infected
CFBE41o; $p<0.05, $ $ $p<0.001 compared to P. histicola; ##<0.01 P. histicola/siRNA TLR2 vs TLR5.
https://doi.org/10.1371/journal.pone.0235803.g004
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flagellin signalling through TLR5 is well-established [48, 49] and induces the canonical pro-
inflammatory NF-κB pathway [50–52]. In several Prevotella species none or only one flagella
synthesis pathway gene has been identified [53]. Therefore, our data may suggest that Prevo-
tella spp. could use other structures for attachment and motility and TLR5 engagement. In sup-
port of this, recent work in neurons and neuropathic pain strongly suggests TLR5 activation
could also be facilitated by non-flagellin small molecules [54]. Further, H. pylori has been
shown to activate TLR5 through CagL, a component of its type IV secretion system, which acts
as a flagellin-independent TLR5 activator [55]. While our experiments show TLR5 signalling
by P. histicola, we did not further investigate flagellin expression in the P. histicola strain used,
nor did we investigate non-specific TLR5 activation in our experimental cell model. Further-
more, we used flagellin derived from Salmonella, which was highly pro-inflammatory, but we
cannot exclude that other flagellins (e.g. from P. aeruginosa) may provoke a response of differ-
ent intensity.
As we observed a strong phosphorylation of IKKα induced by P. histicola, we further sought
to establish if such IKKα activation was involved in the activation of the alternative NF-κB sig-
nalling pathway and if this would have any regulatory effect on the canonical pathway. Knock-
down of IKKα significantly reduced P. histicola induced activation of the alternative NF-κB
signalling (RelB-DNA binding), but we saw an induction in p65 (see ‘scrambled and P. histi-
cola’ in Fig 3C) indicating a role for IKKα in the regulation and suppression of p65.
In normoxia, HIF expression is regulated through hydroxylation by prolyl-4-hydroxylases
(PHDs) and subsequent polyubiquitination promotes HIF degradation [56]. However, epithe-
lial stretch has been shown to stabilise HIF1α (through inhibition of succinate dehydrogenase
(SDH) [57]. During hypoxia, the activity of PHDs is suppressed, allowing HIF-1α to translo-
cate into the nucleus where it binds to its dimerization partner HIF1B and enhances the tran-
scription of HIF target genes [56]. HIF-1α stabilization during hypoxia is achieved through
RSUME/SUMO, where RSUME (RWD-containing sumoylation enhancer) increases the con-
jugation of SUMO (small ubiquitination modifier) and stabilizing HIF-1α [26]. IKBα is simi-
larly stabilized during hypoxia, inhibiting NF-κB activation and signalling, indicating a role
for hypoxia induced HIF-1α in the regulation of NF-κB [26]. In support of this regulatory
function of HIF-1α, pharmacological in vivo studies in acute lung injury (ALI) have shown
that HIF-1α stabilization attenuates pulmonary oedema and lung inflammation [57]. In our
study HIF-1α protein was induced in response to infection with P. histicola (in hypoxic condi-
tions) mediated by TLR5, suggesting that TLR5 in addition to inducing inflammation may
also have a regulatory role in the inflammatory response through HIF-1α. HIF-1α activation
induces several cytokines such as TNFα, IL-1, IL-4, IL-6 and IL-12 [58]. After P. histicola infec-
tion, we show a significant upregulation of IL-6 expression, a cytokine known for both pro-
inflammatory and anti-inflammatory actions [59].
Furthermore, RelB may exert a suppressive effect on HIF-1α as we observed an inverse rela-
tionship between IKKα induction (Fig 3A) and HIF-1α expression (Fig 4A). However, as we
have analysed total HIF1α, further research will be required to substantiate this hypothesis.
Limitations to the experimental design include the inability of the CFBE41o- cells to remain
viable and responsive to infection past four hours. In contrast, a study by Schaible et al. accli-
matised airway epithelial cells to hypoxia by incubation in hypoxic condition for 24 hours,
although for CFBE41o- cells no information of cell viability is given [32]. Using 3 different
assays to determine cell viability (MTT formation, LDH release, trypan Blue exclusion assay),
in our cell culture system CFBE41o- cells show a significant reduction in cell viability 6 hours
after the introduction of hypoxia (S2A–S2C Fig), which made it necessary to perform experi-
ments for 4 hours. Although this appears to be a short time point for cytokine release, using a
similar time point, Veit et al. showed detectable cytokine levels in CFBE41o- cells [60].
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A further limitation of this study is the use of only one P. histicola clinical strain. We opted
for the comparison of a clinical P. histicola strain with a clinical P. aeruginosa strain to
reflect clinical conditions. Finally, this study was performed in one CF epithelial cell line
(CFBE41o- cells) and, as we were interested in the different responses of CF relevant pathogens
Fig 5. P. histicola signalling–Schematic representation. Canonical NF-κB signalling pathway (left) utilising p65/p50 and the alternative NF-κB signalling pathway
(right) signalling through RelB. While P. aeruginosa and flagellin signal through TLR4 / TLR5-NF-κB (p65), P. histicola signals through TLR5 activating the alternative
NF-kB (RelB) pathway. HIF1α mediates this signalling through activation of IKKα. However, RelB might introduce a negative feedback on HIF-1a and may also inhibit
IKbα. Proteins determined within the study are highlighted in colour.
https://doi.org/10.1371/journal.pone.0235803.g005
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(P. histicola versus P. aeruginosa), we did not perform the experiments in non-CF airway cells
or CFTR corrected CF epithelial cells. TLR signalling was also investigated using human
embryonic kidney (HEK) 293 reporter cells (InvivoGen), which are specially engineered to
constitutively express a given functional pathogen recognition receptor gene and are not
expected to express CFTR. Our results need to be confirmed using differentiated primary epi-
thelial cells (CF and non-CF), particularly since mucus production would be expected to con-
tribute to anaerobic conditions in the airway.
Despite these limitations, this study is the first to show the signalling pathway of P. histicola
in CF bronchial epithelial cells leading to TLR5 activation resulting in the activation of the
alternative NF-κB signalling pathway. Our work also raises the possibility of a flagellin-inde-
pendent process, which needs further investigation. This is also the first study showing
TLR5-RelB signalling for a clinical isolate of P. histicola. Furthermore, we have identified a
role for IKKα in the regulation of inflammation in response to infection with P. histicola and
this may explain the correlation between elevated levels of anaerobes in the microbiome and
better lung function in CF patients [29]. Prevotella spp. in the gut microbiome display substan-
tial genomic diversity between strains [61], but these studies have also identified beneficial and
detrimental roles for these bacteria, demonstrating that each species may have dual roles in the
microbiome and that further studies are required before we can fully appreciate the role of Pre-
votella spp. in disease and health [62–64].
Conclusion
Anaerobic bacteria such as Gram-negative Prevotella spp. are frequently found in the airways
from healthy volunteers and CF patients, but no studies have examined the role of P. histicola
in modulating inflammatory pathways in CF airway. Our study demonstrates for the first time
important differences in the activation of the NF-kB pathway in anaerobic CF lung inflamma-
tion between P. histicola and P. aeruginosa, and shows a relationship between the alternative
NF-κB signalling pathway (utilised by P. histicola) and the HIF-1α signalling pathway (sum-
marised in Fig 5). Overall, our work suggests that different species of bacteria present in the
respiratory microbiome can contribute differently to inflammation in the CF lung, either by
activating inflammatory cascades (e.g P. aeruginosa) or by muting the inflammatory response
to infection by modulating similar or related pathways (as shown for P. histicola). Further
work is required to assess the complex interactions of the lung microbiome in response to bac-
terial infections and their positive effects in people with CF.
Supporting information
S1 Text. Materials & methods.
(DOCX)
S1 Fig. Growth rate of P. histicola and P. aeruginosa. Growth rate of P. histicola B011L and
P. aeruginosa B021 under anaerobic conditions as described in supporting information above.
All data n = 3–4 with 2way ANOVA with Bonferroni correction.
(TIF)
S2 Fig. Cell viability under aerobic and anaerobic conditions. (A) Mitochondrial activity of
CFBE41o- cells (MTT assay); (B) % LDH release from CFBE41o- cells and (C) uptake of Try-
pan blue by CFBE41o- cells incubated under anaerobic and aerobic conditions as described in
supporting information above. All data n = 4 with 2way ANOVA with Bonferroni correction,
�p<0.05, ��p<0.01.
(TIF)
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S3 Fig. Cell viability during transfection. Lactate dehydrogenase (LDH) release from
CFBE41o- cells after 0-96h of transfection with Lipofectamine 2000 (0.5–1.5 ng/ml) in the
presence and absence of ALL-STARS Hs cell death siRNA (Qiagen) to assess transfection effi-
ciency. All n = 3, �p<0.05 compared to control. 2-Way ANOVA with Bonferroni post-test,
overall ANOVA given within the graph.
(TIF)
S4 Fig. Transfection efficiency for target genes. Efficiency for transfection was assessed by
transfecting cells with TLR5 siRNA followed by the addition of either P. histicola (B011L), P.
aeruginosa and flagellin and calculated relative to the induced response. (A) Significant reduc-
tion in TLR5 mRNA (55% and 60% in response to P. histicola and P. aeruginosa infection,
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